hepatocellular cancinoma
Conditions
Interventions
Treatment group:Continuous hepatic arterial infusion chemotherapy combined with oral lenvatinib treatment
Sponsors
Fujian Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.The age is 18-70 years old, regardless of gender; 2.The diagnostic criteria of hepatocellular carcinoma were based on the criterion of diagnosis and treatment of primary liver cancer (2019 Edition) issued by the National Health Commission; Staging using BCLC staging standards; 3.There was at least one measurable lesion in accordance with RECIST v1.1; 4.Child Pugh liver function rating: A, B grade; 5.ECOG score was 0-2; 6.Bone marrow function (hemoglobin >= 10 g / dl, leukocyte >= 3000 / µ L, platelet >= 75000 / µ L), liver function (bilirubin <= 3 mg / dl, transaminase <= 200 U / L), kidney function (muscle liver <= 390 µ mol / L). The coagulation function was normal; 7.Men and women of childbearing age agreed to contraception during and within 8 weeks after discontinuation.
Exclusion criteria
Exclusion criteria: 1.BCLC stage C patients who are suitable for surgical resection; 2.Coagulation dysfunction (APTT > 1.5uln or INR > 1.5); 3.Acute infection or sepsis; 4.During pregnancy and lactation; 5.There were active bleeding, hypertension within 30 days after major operation, uncontrollable by drugs, and severe renal insufficiency (IV); 6.The expected survival time was less than 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival;Enhanced CT or MR examination of the upper abdomen;Tumor response assessment criteria;Time to tumor progression; | — |
Countries
China
Contacts
Public ContactChen Shiguang
Fujian Cancer Hospital
Outcome results
None listed